ATE538802T1 - Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung - Google Patents

Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung

Info

Publication number
ATE538802T1
ATE538802T1 AT06727501T AT06727501T ATE538802T1 AT E538802 T1 ATE538802 T1 AT E538802T1 AT 06727501 T AT06727501 T AT 06727501T AT 06727501 T AT06727501 T AT 06727501T AT E538802 T1 ATE538802 T1 AT E538802T1
Authority
AT
Austria
Prior art keywords
protein
env gene
gene encoded
endogenous retrovirus
env
Prior art date
Application number
AT06727501T
Other languages
English (en)
Inventor
Marianne Mangeney
Martial Renard
Therry Heidmann
Julien Pothlichet
Marie Dewannieux
Original Assignee
Viroxis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viroxis filed Critical Viroxis
Application granted granted Critical
Publication of ATE538802T1 publication Critical patent/ATE538802T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06727501T 2005-03-30 2006-03-30 Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung ATE538802T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66617805P 2005-03-30 2005-03-30
PCT/IB2006/000921 WO2006103562A2 (en) 2005-03-30 2006-03-30 Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment

Publications (1)

Publication Number Publication Date
ATE538802T1 true ATE538802T1 (de) 2012-01-15

Family

ID=36759031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06727501T ATE538802T1 (de) 2005-03-30 2006-03-30 Endogener retrovirus und proteine, kodiert durch env-gen, als target für die krebsbehandlung

Country Status (5)

Country Link
EP (2) EP2402447A1 (de)
AT (1) ATE538802T1 (de)
DK (1) DK1871391T3 (de)
ES (1) ES2380228T3 (de)
WO (1) WO2006103562A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
AU2008252935B2 (en) 2007-05-24 2013-01-31 Baxter Healthcare Sa Antibodies useful for therapy and diagnosis of cancer
WO2010030931A1 (en) 2008-09-11 2010-03-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Oligonucleotides targeting human endogenous retrovirus 9 (erv-9) long terminal repeat (ltr) and methods of use
WO2010032696A1 (ja) * 2008-09-18 2010-03-25 学校法人慶應義塾 がんの診断方法と治療方法
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
US9878002B2 (en) 2013-01-25 2018-01-30 Regents Of The University Of Minnesota Compositions and methods involving endogenous retrovirus proteins
EP3760208B1 (de) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting von humanem satellit ii (hsatii)
US20190038659A1 (en) * 2015-09-29 2019-02-07 The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing amyotrophic lateral sclerosis
WO2019043127A1 (en) * 2017-09-01 2019-03-07 Inprother Aps VACCINE FOR USE IN PROPHYLAXIS AND / OR TREATMENT OF DISEASE
KR20210055725A (ko) * 2018-09-06 2021-05-17 상뜨로 레옹 베라르 항암 백신을 위한 공유된 종양 항원으로서 herv-k-유래된 항원
CN112867501B (zh) 2018-10-19 2025-01-07 弗朗西斯·克里克研究所有限公司 新的癌抗原和方法
EP3990006A1 (de) 2019-06-28 2022-05-04 The Francis Crick Institute Limited Neuartige krebsantigene und verfahren
KR20220029560A (ko) 2019-06-28 2022-03-08 더 프란시스 크릭 인스티튜트 리미티드 신규한 암 항원 및 방법
BR112022000020A2 (pt) 2019-07-05 2022-05-24 Enara Bio Ltd Antígenos de câncer inovadores e métodos
BR112022000133A2 (pt) 2019-07-05 2022-04-12 Enara Bio Ltd Antígenos de câncer e métodos
CA3179694A1 (en) 2020-04-17 2021-10-21 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
WO2021209775A1 (en) 2020-04-17 2021-10-21 The Francis Crick Institute Limited Antigen pool
GB202102118D0 (en) * 2021-02-15 2021-03-31 Cambridge Entpr Ltd RNA Trans-Splicing molecule
WO2025046393A1 (en) * 2023-08-25 2025-03-06 Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) Reagents against human endogenous retroviruses to target cancer cells
CN119751661A (zh) * 2024-12-16 2025-04-04 浙江大学 抗herv-k102-su鼠源抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770456B1 (en) * 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
FR2797889A1 (fr) * 1999-09-01 2001-03-02 Bio Merieux Procede de detection de l'expression d'une proteine d'enveloppe d'un retrovirus endogene humain et utilisations d'un gene codant pour cette proteine
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
EP1521594B1 (de) * 2001-12-07 2013-10-02 Novartis Vaccines and Diagnostics, Inc. Mit onkogener transformation in verbindung gebrachte endogene retroviruspolypeptide
WO2004087748A1 (en) 2003-04-04 2004-10-14 Centre National De La Recherche Scientifique Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same
ES2347445T3 (es) 2004-03-30 2010-10-29 Institut Gustave Roussy Secuencia polipeptidica implicada en la modulacion del efecto inmunosupresor de las proteinas viricas.

Also Published As

Publication number Publication date
WO2006103562A3 (en) 2007-03-15
EP2402447A1 (de) 2012-01-04
DK1871391T3 (da) 2012-04-16
EP1871391A2 (de) 2008-01-02
EP1871391B1 (de) 2011-12-28
WO2006103562A2 (en) 2006-10-05
ES2380228T3 (es) 2012-05-09

Similar Documents

Publication Publication Date Title
WO2006103562A3 (en) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
EA200601946A3 (ru) Антитела, связывающиеся с белками steap-1, и их производные
NZ619576A (en) Compositions and methods for the treatment of infections and tumors
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
EA201590986A1 (ru) Антитела к ceacam5 и их применения
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
TN2009000194A1 (en) Novel antiproliferation antibodies
BR112012020373A8 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
WO2004046332A3 (en) Amplified genes involved in cancer
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2003079982A3 (en) Gene amplification in cancer
EA202092518A1 (ru) Композиции и способы лечения рака
WO2003100000A3 (en) Amplification and overexpression of oncogenes
ATE514718T1 (de) Peptabody für krebsbehandlung
WO2003044161A3 (en) Gene amplification and overexpression in cancer
DE602004027647D1 (de) An ovarialkrebs beteiligtes protein
WO2006138745A3 (en) Therapeutic peptides and vaccines
WO2004015063A3 (en) Amplification and overexpression of oncogenes
WO2003054512A3 (en) Identification of an amplified gene and target for drug intervention
WO2004112575A3 (en) Gene amplification and overexpression in cancer
MA48487B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
DE60226956D1 (de) Verstärktes krebs-gen wip1